New drug combo targets Hard-to-Treat brain tumors

NCT ID NCT07652762

Recruiting now Disease control Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This early-stage trial tests two oral drugs, IN10018 and dalpiciclib, in 24 adults with progressive meningiomas (brain tumors that keep growing despite treatment). The main goal is to check safety and find the best dose. Researchers will also see if the combination can shrink tumors or slow their growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IN10018 (ifetemtinib) and dalpiciclib
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for people with progressive meningiomas that have not responded to standard therapy.
What could go wrong: This is a very early Phase 1 study with only 24 participants, so the main goal is safety, not proof of effectiveness. The drugs may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CDK4/6 INHIBITOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CDK4/6 INHIBITOR MENINGIOMA

Contacts and locations

Locations

Beijing Sanbo Brain Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100093, China
Sanbo Brain Hospital, Capital Medical University
NOT_YET_RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.